01—Abstract
Summary
Summary of the 10-Q filed April 23, 2024. Cited figures are marked; the original filing is the authoritative source.
Danaher's first quarter 2024 results (quarter ended March 29, 2024) show a clear top-line and margin slowdown, concentrated in its Biotechnology segment.
Total sales fell 2.5% year-over-year to $5.80 billiona, while core sales (excluding acquisitions and currency) declined 4.0%. Diluted EPS from continuing operations was $1.45, down from $1.65 a year earlier, and operating margin compressed 290 basis points to 22.6%. Management attributes the weakness mainly to a sharp decline in Biotechnology sales (down 18.0% reported, 17.0% core), driven by bioprocessing customers cutting inventory and emerging biotech customers conserving capital amid a tighter funding environment.
Management expects bioprocessing core revenue to decline for full-year 2024, with gradual improvement through the year. Diagnostics was the bright spot, with sales up 6.5%b and operating margin up 430 basis points to 32.8%, led by molecular diagnostics. The balance sheet and cash position look solid, though with some caveats.
Cash and equivalents rose to $7.0 billionc from $5.9 billion, and operating cash flow from continuing operations was $1.7 billion. However, the increase in cash was helped by a sizable foreign currency translation loss of $948 million that hit comprehensive income, which fell to $92 million from $1.56 billion. Total debt was $18.2 billion, and the company repaid a €900 million Euronote on April 2, 2024 using cash distributed by Veralto before the separation.
Goodwill and intangibles remain large, at roughly $60.7 billiond combined, and the company reported no impairment triggers. Quarterly results are also not directly comparable with the prior year, since they exclude Veralto (a discontinued operation) and include the Abcam acquisition.
02—Key points
Key Highlights
- Total sales declined 2.5% to $5,796 million; core sales fell 4.0%, with acquisitions adding 2.0% and currency subtracting 0.5%.
- Biotechnology sales fell 18.0% to $1,524 million and operating margin dropped to 21.3% from 32.0%, reflecting weak bioprocessing demand and customer inventory reductions in China, Western Europe and North America.
- Diagnostics was the standout segment, with sales up 6.5% to $2,527 million and operating margin expanding to 32.8% from 28.5%, driven by molecular diagnostics growth.
- Diluted EPS from continuing operations was $1.45 versus $1.65 a year ago; net earnings from continuing operations were $1,088 million versus $1,240 million.
- Gross margin fell to 60.2% from 61.6%, partly due to a $25 million acquisition-related inventory fair value step-up tied to the Abcam acquisition.
- Cash and equivalents rose to $7.0 billion, while total debt was $18.2 billion; the company repaid a €900 million Euronote on April 2, 2024.
- Comprehensive income fell to $92 million from $1,556 million, driven by a $948 million foreign currency translation loss; the company expects a full-year 2024 effective tax rate of about 17.5%.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Danaher Corp kept $0.19.
- Revenue$5.80B100.0%
- Cost of revenue−$2.31B39.8%
- Gross profit$3.49B60.2%
- Operating costs−$2.17B37.5%
- Operating income$1.31B22.6%
- Interest, other & tax−$224.0M3.9%
- Net income$1.09B18.8%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 23, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $5.80B$5.95B | −2.6% |
| Cost of Revenue | $2.31B$2.29B | +1.0% |
| Gross Profit | $3.49B$3.66B | −4.8% |
| R&D Expenses | $368.00M$373.00M | −1.3% |
| SG&A Expenses | $1.81B$1.77B | +2.0% |
| Operating Income | $1.31B$1.52B | −13.5% |
| Interest Expense | $65.00M$66.00M | −1.5% |
| Net Income | $1.09B$1.43B | −23.9% |
| EPS (Basic) | $1.47$1.96 | −25.0% |
| EPS (Diluted) | $1.45$1.94 | −25.3% |
| Shares Outstanding (Basic) | 740.60M729.40M | +1.5% |
| Shares Outstanding (Diluted) | 748.60M737.20M | +1.5% |
05—Questions
Frequently Asked Questions
Why did Danaher's Biotechnology segment decline so sharply in Q1 2024?
Biotechnology sales fell 18.0% (17.0% on a core basis), led by bioprocessing, where core sales dropped at a high-teens rate. Management cited customers reducing inventory levels, a tighter credit environment that curtailed spending by emerging biotech companies, and lower demand for protein research products in the discovery and medical business. Management expects reduced demand to persist into the second quarter of 2024 and bioprocessing core revenue to decline for full-year 2024, with gradual improvement through the year.
Is Danaher's margin compression a one-time issue or a structural concern?
The 290 basis point decline in operating margin to 22.6% reflects several factors: lower core sales, product mix, reduced operating leverage (170 bps), dilution from the acquired business (80 bps), and the Abcam inventory step-up charge (40 bps). The dilution and inventory charge are largely non-recurring or tied to the acquisition. The leverage and mix effects depend on whether the Biotechnology downturn is cyclical, a question the filing does not resolve.
How strong is Danaher's liquidity and debt position after the Veralto separation?
Cash and equivalents increased to $7.0 billion, with about $2.8 billion held in the U.S. and $4.2 billion abroad. Operating cash flow from continuing operations was $1.7 billion for the quarter. Total debt was $18.2 billion, and the company stated it was in compliance with all debt covenants. Management believes it has sufficient liquidity, supported by its $5.0 billion revolving credit facility and commercial paper program.
What drove the drop in comprehensive income and what does it mean for shareholders?
Comprehensive income fell to $92 million from $1,556 million, mainly due to a $948 million foreign currency translation loss, primarily from the U.S. dollar's strengthening against the Swedish krona and other currencies. These losses are unrealized and recorded in equity rather than net earnings, so they do not reduce reported earnings. However, they reduce book equity, which declined only modestly to $53.4 billion because of offsetting gains elsewhere.
Are the Q1 2024 results comparable to last year's?
Not directly. The prior-year quarter included Veralto, which was spun off on September 30, 2023 and is reported as discontinued operations. The prior-year net earnings of $1.45 billion included $210 million from discontinued operations. Continuing-operations comparisons are therefore the more relevant measure. The current year also includes the Abcam acquisition, which contributed 2.0 percentage points to sales growth and dilutes margins.
06—Continue